Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

A single-center experience of 2000 adult lung transplants.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Trends in primary graft dysfunction and early mortality following lung transplantation: A single center experience.

JHLT open·2026
Same author

Venous Thromboembolism in Brain-Dead Organ Donors: A Prospective Study of Prevalence, Management, and Impact on Organ Utilization and Recipient Outcomes.

Clinical transplantation·2025
Same author

The NHLBI lung transplant consortium 2025 steering committee report: Strategies to maximize the use of the consortium for advancing lung transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Atg16l1 promotes lung transplant tolerance by regulating glycolysis in macrophages.

bioRxiv : the preprint server for biology·2025
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 12, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

Immunosuppression: Have We Learnt Anything?

Ramsey R Hachem1

  • 1Division of Pulmonary and Critical Care, Washington University School of Medicine, St. Louis, Missouri.

Seminars in Respiratory and Critical Care Medicine
|March 27, 2018
PubMed
Summary
This summary is machine-generated.

Lung transplant outcomes are poor due to chronic lung allograft dysfunction (CLAD). Clinical trials on immunosuppression show mixed results, highlighting the need for better strategies to prevent CLAD and improve survival.

More Related Videos

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

11.9K
A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.6K

Related Experiment Videos

Last Updated: Feb 12, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

11.9K
A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.6K

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Clinical Trials

Background:

  • Lung transplantation outcomes are limited by high rates of chronic lung allograft dysfunction (CLAD).
  • CLAD, primarily caused by chronic rejection, leads to allograft failure and patient death.
  • Optimizing immunosuppression is crucial for preventing CLAD and enhancing long-term survival post-transplant.

Purpose of the Study:

  • To review clinical trials investigating immunosuppressive agents in lung transplantation.
  • To analyze the efficacy and safety of various immunosuppression strategies.
  • To identify current practices, limitations, and knowledge gaps in lung transplant immunosuppression research.

Main Methods:

  • Systematic review of clinical trials in lung transplantation.
  • Analysis of study designs, patient populations, and outcomes related to immunosuppression.
  • Evaluation of strengths and limitations of conducted trials, from single-center to multicenter studies.

Main Results:

  • Numerous trials have assessed different immunosuppressive agents, with varying scales and designs.
  • Evidence from trials informs current lung transplant practices but reveals inconsistencies.
  • Limitations in trial methodologies and reporting impact definitive conclusions on optimal immunosuppression.

Conclusions:

  • Current immunosuppression strategies have not fully overcome the challenge of CLAD after lung transplantation.
  • Further well-designed clinical trials are essential to refine immunosuppressive protocols.
  • Improved immunosuppression is critical for advancing lung transplant outcomes and patient survival.